Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products

Peritoneal Dialysis International

Volumn 24, Issue 1, 2004, Pages 48-57

  Wieczorowska Tobis, Katarzyna ^a   Brelinska, Renata ^a   Witowski, Janusz ^a   Passlick Deetjen, Jutta ^b   Schaub, Thomas P ^b   Schilling, Holger ^b   Breborowicz, Andrzej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Animal models; Biocompatibility; Glucose degradation products; Peritoneal dialysis fluids; Peritoneal Eosinophilia

Indexed keywords

CREATININE; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; RANTES; SODIUM; UREA; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CELL DENSITY; CELL JUNCTION; CONCENTRATION RESPONSE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE; EOSINOPHILIA; EXPERIMENTAL MODEL; GERMANY; LONG TERM EXPOSURE; MALE; MEMBRANE PERMEABILITY; MESOTHELIUM CELL; NONHUMAN; PERITONEUM; PERITONITIS; PH; PRESERVATION; PRIORITY JOURNAL; RAT; UREMIA;

EID: 3042734259     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080402400105     Document Type: Article

References (37)

1. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
2. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498-506.
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
4. Ota K, Mineshima M, Watanabe N, Naganuma S. Functional deterioration of the peritoneum: does it occur in the absence of peritonitis? Nephrol Dial Transplant 1987; 2:30-3.
5. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995; 15:158-64.
6. Jonasson P, Braide M. Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages. Perit Dial Int 1998; 18:376-81.
7. Wieslander AP, Nordin MK, Martinson E, Kjellstrand PT, Boberg UC. Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 1993; 39:343-8.
8. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
9. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
10. Jonasson P, Braide M. Kinetics and dose response of the effects of heated glucose peritoneal dialysis fluids on the respiratory burst of rat peritoneal leukocytes. ASAIO J 2000; 46:469-73.
11. Simonsen O, Wieslander A, Landgren C, Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. Adv Perit Dial 1996; 12:156-60.
12. Lage C, Pischetsrieder M, Aufricht C, Jorres A, Schilling H, Passlick-Deetjen J. First in vitro and in vivo experiences with stay-safe balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000; 20(Suppl 5):S28-32.
13. Cappelli G, Bandiani G, Cancarini GC, Feriani M, Dell'Aquila R, Saffioti S, et al. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag. Adv Perit Dial 1999; 15:238-42.
14. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
15. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
16. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20:516-23.
17. Wieczorowska-Tobis K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, et al. Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats. Perit Dial Int 2001; 21(Suppl 3):S108-13.
18. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, et al. In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280: 1408-14.
19. Wieczorowska-Tobis K, Korybalska K, Polubinska A, Radkowski M, Breborowicz A, Oreopoulos DG. In vivo model to study the biocompatibility of peritoneal dialysis solutions. Int J Artif Organs 1997; 20:673-7.
20. Wieczorowska-Tobis K. Przewlekla dializa otrzewnowa u szczura jako model do badania biozgodnosci plynow dializacyjnych [Thesis/Dissertation]. [Chronic peritoneal dialysis in rat as a model to study the biocompatibility of dialysis fluids.] University Medical School, Pozńan, Poland; 2001.
21. Guo W, Willen R, Andersson R, Parsson H, Liu X, Johansson K, et al. Morphological response of the peritoneum and spleen to intraperitoneal biomaterials. Int J Artif Organs 1993; 16:276-84.
22. Suzuki K, Khanna R, Nolph KD, Twardowski ZJ, Moore HL. Expected white blood cell counts and differentials in a rat model of peritoneal dialysis. Perit Dial Int 1995; 15:142-6.
23. Pecoits-Filho RF, Twardowski ZJ, Khanna R, Kim YL, Goel S, Moore H. The effect of antibiotic prophylaxis on the healing of exit sites of peritoneal dialysis catheters in rats. Perit Dial Int 1998; 18:60-3.
24. Lowry OH, Rosenbrough NJ, Rarr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-75.
25. Wieczorowska-Tobis K, Polubinska A, Brelinska R, Breborowicz A. The ultrastructure of the peritoneal membrane in chronically dialysed rats. Folia Histochem Cytobiol 2001; 39:209-10.
26. Musi B, Carlsson O, Rippe A, Wieslander A, Rippe B. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998; 18:303-10.
27. Musi B, Braide M, Wieslander A, Rippe A, Albrektsson A, Henle T, et al. Very high daily intraperitoneal doses of carbonyl compounds affect the morphology, but not the exchange characteristics, of rat peritoneum. Blood Purif 2001; 19:286-92.
28. Miyata T, van Ypersele DS, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999; 55:389-99.
29. Miyata T, Izuhara Y, Sakai H, Kurokawa K. Carbonyl stress: increased carbonyl modification of tissue and cellular proteins in uremia. Perit Dial Int 1999; 19 (Suppl 2):S58-61.
30. Ejaz AA, Fitzpatrick PM, Durkin AJ, Wasiluk A, Haley WE, Goalen MJ, et al. Pathophysiology of peritoneal fluid eosinophilia in peritoneal dialysis patients. Nephron 1999; 81:125-30.
31. Chan MK, Chow L, Lam SS, Jones B. Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study. Am J Kidney Dis 1988; 11:180-3.
32. Nakamura Y, Okada H, Yasui A, Koh T, Yamane T. Sclerosing encapsulating peritonitis associated with recurrent eosinophilic peritonitis. Nephrol Dial Transplant 1999; 14:768-70.
33. Graziano FM, Cook EB, Stahl JL. Cytokines, chemokines, RANTES, and eotaxin. Allergy Asthma Proc 1999; 20:141-6.
34. Rollins BJ. Chemokines. Blood 1997; 90:909-28.
35. Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 2001; 22:133-7.
36. Izumi S, Hirai K, Miyamasu M, Takahashi Y, Misaki Y, Takaishi T, et al. Expression and regulation of monocyte chemoattractant protein-1 by human eosinophils. Eur J Immunol 1997; 27:816-24.
37. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14:1296-306.